NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00128778,Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients,https://clinicaltrials.gov/study/NCT00128778,,COMPLETED,"This is a randomized, prospective and multicenter phase IV clinical trial, which has been designed as a phase III study. One hundred fifty-four women (77 per treatment arm) will be recruited in the study.",NO,Breast Neoplasms,DRUG: Pegylated liposomal doxorubicin,"Time to progression (TTP), Tumor assessments will be performed until disease progression in order to evaluate the TTP. TTP is defined as the time from the date of the first dose to the first date of objectively determined progressive disease. For patients not known to have objectively-determined progressive disease, TTP will be censored at the date of the last objective progression-free assessment. For patients who receive subsequent systemic anticancer therapy (after discontinuation from the study treatment) prior to objective disease progression, TTP will be censored at the date of last objective progression-free assessment prior to the initiation of postdiscontinuation systemic anticancer therapy., Through study completion, an average of 1 year",,,Spanish Breast Cancer Research Group,Schering-Plough,FEMALE,"ADULT, OLDER_ADULT",PHASE4,288,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GEICAM 2001-01,2002-10-28,2007-06-01,2010-07-07,2005-08-10,,2023-03-06,"Spanish Breast Cancer Research Group (GEICAM), San Sebasti√°n de los Reyes, Madrid, 28700, Spain",
